Fibrinogen-coated albumin spheres to accelerate bone healing in older adults

Active Grant Awarded

Award ID
R44AG099306
Recipient
Awarding agency
Obligated
$1,162,390

Award facts

Assistance listing
93.866 Aging Research
Completion date 10% complete
Place of performance
Las Vegas, NV 89118, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, through the National Institute on Aging, awarded Fibroplate Inc. a grant of $1,162,390 on September 17, 2026, under the Aging Research program (CFDA 93.866). The award funds Fibrinoplate-S (FPS), an intravenous injectable based on fibrinogen-coated albumin nano-spheres, intended to accelerate bone healing in older adults. Per the project summary, FPS would be administered intravenously after the first bone trauma treatment in both surgical and nonsurgical settings, reaching bone marrow stem cells and stimulating their mobilization toward the lesion. The summary describes FPS as safe with no side effects for frail elderly patients who cannot tolerate invasive or toxic approaches, and states that faster healing would reduce morbidity, mortality, and lost productivity associated with fractures in older adults.

Dollars obligated total $1,162,390. The period of performance runs from the September 17, 2026 award date to an ultimate completion date of May 31, 2028. Work is performed in Las Vegas, Nevada 89118.

The Aging Research program supports biomedical, social, and behavioral research on the aging process and on the diseases and needs of aging people, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
The incidence of bone fracture is higher in aged people due to conditions associated with bone fragility such as osteoporosis, and osteopenia, and a higher rate of falls caused by visual impairment. Additionally, the bone healing process in the elderly is compromised due to age-related changes in inflammatory regulation, cellular differentiation, and signaling cascades, with almost 25% of fractured older adults experiencing second bone injury within 5 years. Improved healing of first fractures will help reduce the long-term economic and clinical burden, however, to date, there is no gold-standard adjunctive treatment to accelerate the healing process in frail and aged patients. Fibroplate proposes fibrinoplate-S (FPS), an intravenous (IV) injectable product based on fibrinogen-coated albumin nano-spheres (FAS) as a novel approach to promote bone regeneration in older adults. FPS will change the clinical practice in geriatric fracture management by introducing a safe and biological treatment that improves and accelerates the bone healing process. FPS will be administered IV after the first bone trauma treatment, both in surgical and nonsurgical clinical scenarios. The IV administration will allow FPS to reach the bone marrow stem cells and stimulate their mobilization toward the site of the lesion. FPS is safe with no side effects, allowing effective treatment in frail elderly patients, who cannot tolerate invasive and toxic approaches. By reducing the healing period and enhancing the complete recovery process, FPS will reduce the morbidity, mortality, and loss of productivity associated with bone fractures in the elderly. The ability to promote the biological pathways supporting bone repair will also reduce the risk of subsequent fractures and the additional care costs associated with long hospitalization and rehabilitation periods in specialized clinical settings. The completed sbir phase I grant confirmed that IV administration of FPS boosted mineralized callus development at the fracture site 21 days after the bone fracture, but with a modest impact for mineralized bridging at the callus site, torsional strength or stiffness after 35 days post-injury. In this sbir phase II project, we aim to investigate whether multiple IV administration of FPS is capable of fully restoring bone functionality in aged rats and conduct missing investigational new drug (IND)-enabling studies to support an IND meeting with the FDA. Fibroplate will gather pharmacokinetics (PK), pharmacodynamics (PD), absorption, distribution, metabolism, and excretion (ADME) (aim 1); and establish the efficacy of multiple dosages of FPS in promoting functional fracture recovery in aged rats (aim 2). After successful completion of the proposed sbir phase II grant, fibroplate will move to larger models of bone fracture and will also start the preparation of an IND package preparation, which will be finalized after a pre-IND request to the FDA.

Quick answers

Who received award R44AG099306?

R44AG099306 was awarded to Fibroplate Inc. by National Institute on Aging (National Institutes of Health) on September 17, 2026.

How much is award R44AG099306 worth?

$1,162,390 has been obligated on R44AG099306.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award